Interleukin-17 (IL-17) Inhibitors in Plaque Psoriasis Treatment

Article

Interleukin-17, one of the T-helper 1 (Th17) subtypes had been reported to be a significant trigger for plaque psoriasis however the specific contribution of each cytokine group still remains questionable.

Interleukin-17, one of the T-helper 1 (Th17) subtypes had been reported to be a significant trigger for plaque psoriasis however the specific contribution of each cytokine group still remains questionable.

IL-17 has been noted; however, to act on keratinocytes to produce antimicrobial peptides and chemokines to attract other inflammatory cells.

Both Th1/Th17 cells and their related cytokines have been identified in increased levels within lesional psoriatic skin in several studies. However, outcomes regarding the serum concentration of Th17-related cytokines in psoriasis patients are controversial given that in some studies they were found significantly increased while in others they were not

Researchers from the Department of Dermatology-Venereology, Aristotle University Medical School, Thessaloniki, Greece, examined the specific role IL-17 played in plaque psoriasis pathogenesis — questioning the pros and cons of potential IL-17 inhibition.

The study was published in the Journal of Cutaneous Medicine and Surgery.

The team measured interleukin (IL)-1β, 6, 8, 17Α, 22, and 23’s serum levels and the tumor necrosis factor-α (TNFα) with flow cytometry in 35 patients afflicted with plaque psoriasis (21 with stable and 14 with active disease) and in 20 healthy controls.

Interleukin-6, 8, 17A, 22, 23, and TNFα were significantly elevated in psoriasis patients compared to the placebo group. Sensitivity analyses indicated patients with active disease showed significantly increased levels of IL-17A, IL-23, and IL-22 compared with the group of patients with stable psoriasis.

The study ultimately underscored the vital role of IL-17A, IL-22, and IL-23 in the early stages of psoriasis activity.

The authors concluded, “The efficacy and safety results from Phase 2 and 3 trials with monoclonal antibodies targeting IL-17RA (brodalumab), and IL-17A (ixekizumab and secukinumab) validate IL-17 as an effective therapeutic target for the treatment of plaque psoriasis.”

Related Videos
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
What Should the American Academy of Physician Associates Focus on in 2025?
Danielle O'Laughlin, PA-C, MS: Navigating Long-Term Risks, Family Planning in PCOS
© 2024 MJH Life Sciences

All rights reserved.